
Investments
16Portfolio Exits
2Partners & Customers
1Service Providers
1About Gurnet Point Capital
Gurnet Point Capital is a private equity firm that invests in de-risked life sciences companies. It provides funds across all stages of product development including clinical trial design and execution, drug development, regulatory affairs, toxicology, and other areas related to developing early-stage medicines and devices. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Expert Collections containing Gurnet Point Capital
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Gurnet Point Capital in 1 Expert Collection, including Vitamin & Supplement Startups.
Vitamin & Supplement Startups
237 items
Latest Gurnet Point Capital News
Oct 18, 2023
News provided by Share this article Leadership in attendance in Barcelona ready to talk to potential partners and collaborators GRAND RAPIDS, Mich., Oct. 18, 2023 /PRNewswire/ -- Corium Innovations, Inc. , a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, announced today that it will be featuring its industry leading transdermal, microarray and oral thin film technologies at booth 80N27 during the upcoming CPHI Barcelona 2023, to be held October 24-26 in Barcelona, Spain. With 25 years of making and leveraging groundbreaking transdermal delivery systems since it was founded, Corium Innovations maintains fully integrated research & development capabilities along with annual manufacturing capacity of more than 200 million transdermal patches/films at its 200,000 square foot GMP facility in Grand Rapids, Michigan. Corium Innovations brings the best of its proprietary transdermal and transmucosal delivery platforms to different patient and consumer groups in customary or challenging usage situations. Featuring industry leading transdermal, microarray and oral thin film technologies during CPHI Barcelona 2023 "Our passion for continually cracking the code in drug delivery is proven and enables us to deliver more than medicine. It enables us to deliver healthier outcomes," said Dr. Mark Sirgo, Chief Executive Officer at Corium Innovations. "Our teams of scientists and engineers never stop finding ways to create solutions for partners by adapting our tunable technologies for a vast range of therapies, including biologics. We keep pushing forward to develop high-value brands and complex generic products. Both for the partners we work for today – and for those in the future." Nearly a quarter-century ago, led by Dr. Gary Cleary, Adrian Faasse and their teams set out to use cutting-edge science and engineering to create a bold new world of drug-delivery technologies. Since then, the Corium Innovations team has published 35 scientific papers and more than 90 patents covering a wide range of scientific research in drug delivery, including applications for transdermal, polymer and permeation enhancement technologies. Corium Innovations' proprietary Corplex® transdermal innovation platform breaks new ground in drug delivery with a proprietary mix of adhesives, polymers and liners that can be adjusted for almost any use situation. From teeth whitening strips, to the first and only 7-day continuous treatment patch for Alzheimer's disease, Corplex is helping millions of people get the help and benefits they are seeking in a way that works better for their lives. About Corium Innovations Headquartered in Grand Rapids, Michigan, Corium Innovations is a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies. With a track record spanning nearly 30 years, Corium Innovations offers end-to-end solutions to its partners, from formulation and product development work, through commercial-scale manufacturing and packaging. The company's success is enabled by its state-of-the-art facilities, highly tenured operational leadership, and its proprietary proven drug delivery technology CORPLEX®. For more information, visit https://www.coriuminv.com . About Gurnet Point Capital Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point's team of highly experienced industry executives works closely with its portfolio companies, with an active approach driving operational transformation and outsized returns. www.gurnetpointcapital.com/ About Webster Equity Partners Founded in 2003, Webster is a private equity firm that focuses on high impact growth strategies that seek to deliver optimal outcomes for our investors, portfolio companies and the communities that we serve. Our mission is to deliver superior returns to our partners through the investment in and development of purpose driven patient-centric healthcare organizations dedicated to providing best of class clinical care and service to their patients. https://websterequitypartners.com/ SOURCE Corium Innovations, Inc.
Gurnet Point Capital Investments
16 Investments
Gurnet Point Capital has made 16 investments. Their latest investment was in Naveris as part of their Series A - II on September 9, 2022.

Gurnet Point Capital Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
9/19/2022 | Series A - II | Naveris | $33.4M | No | BrightEdge, and TechU Ventures | 5 |
6/22/2022 | Series D | Alladapt Immunotherapeutics | $119M | No | 8 | |
5/23/2022 | Series A | Fairtility | $15M | Yes | Nacre Capital, and Undisclosed Investors | 1 |
8/11/2021 | Series B | |||||
4/16/2020 | Series A - III |
Date | 9/19/2022 | 6/22/2022 | 5/23/2022 | 8/11/2021 | 4/16/2020 |
---|---|---|---|---|---|
Round | Series A - II | Series D | Series A | Series B | Series A - III |
Company | Naveris | Alladapt Immunotherapeutics | Fairtility | ||
Amount | $33.4M | $119M | $15M | ||
New? | No | No | Yes | ||
Co-Investors | BrightEdge, and TechU Ventures | Nacre Capital, and Undisclosed Investors | |||
Sources | 5 | 8 | 1 |
Gurnet Point Capital Portfolio Exits
2 Portfolio Exits
Gurnet Point Capital has 2 portfolio exits. Their latest portfolio exit was Zikani Therapeutics on April 01, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
4/1/2021 | Acquired | 3 | |||
Date | 4/1/2021 | |
---|---|---|
Exit | Acquired | |
Companies | ||
Valuation | ||
Acquirer | ||
Sources | 3 |
Gurnet Point Capital Acquisitions
4 Acquisitions
Gurnet Point Capital acquired 4 companies. Their latest acquisition was Paratek Pharmaceuticals on September 20, 2023.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
9/20/2023 | Debt | $129.3M | Take Private | 10 | ||
8/15/2022 | Series B | |||||
11/27/2018 | Series C | |||||
7/24/2017 | Other |
Date | 9/20/2023 | 8/15/2022 | 11/27/2018 | 7/24/2017 |
---|---|---|---|---|
Investment Stage | Debt | Series B | Series C | Other |
Companies | ||||
Valuation | ||||
Total Funding | $129.3M | |||
Note | Take Private | |||
Sources | 10 |
Gurnet Point Capital Partners & Customers
1 Partners and customers
Gurnet Point Capital has 1 strategic partners and customers. Gurnet Point Capital recently partnered with Zevra Therapeutics on April 4, 2021.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
4/8/2021 | Licensor | United States | `` The last few weeks since AZSTARYS was approved have been an exciting and busy time as we have worked with our partners at Gurnet Point Capital and Corium to re-evaluate the commercial potential of AZSTARYS based on the final approved label , and negotiated adjustments to the economics of our License Agreement to optimize investment in the commercial launch and , ultimately , long-term value creation . | 1 |
Date | 4/8/2021 |
---|---|
Type | Licensor |
Business Partner | |
Country | United States |
News Snippet | `` The last few weeks since AZSTARYS was approved have been an exciting and busy time as we have worked with our partners at Gurnet Point Capital and Corium to re-evaluate the commercial potential of AZSTARYS based on the final approved label , and negotiated adjustments to the economics of our License Agreement to optimize investment in the commercial launch and , ultimately , long-term value creation . |
Sources | 1 |
Gurnet Point Capital Service Providers
1 Service Provider
Gurnet Point Capital has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Take Private | Investment Bank | Financial Advisor |
Service Provider | |
---|---|
Associated Rounds | Take Private |
Provider Type | Investment Bank |
Service Type | Financial Advisor |
Partnership data by VentureSource
Gurnet Point Capital Team
4 Team Members
Gurnet Point Capital has 4 team members, including current Chief Financial Officer, Gretchen McCarey.
Name | Work History | Title | Status |
---|---|---|---|
Gretchen McCarey | Waypoint Capital, Accomplice, Atlas Venture, Globespan Capital Partners, Sparta Group, Citizens Capital, New England Investment and Retirement Group, and Deloitte | Chief Financial Officer | Current |
Name | Gretchen McCarey | |||
---|---|---|---|---|
Work History | Waypoint Capital, Accomplice, Atlas Venture, Globespan Capital Partners, Sparta Group, Citizens Capital, New England Investment and Retirement Group, and Deloitte | |||
Title | Chief Financial Officer | |||
Status | Current |
Loading...